Posted: 21 June 2023
Transformative cancer diagnostic technology, Rhythm Biosciences Ltd is pleased to provide an update regarding the technical feasibility pipeline expansion initiatives/opportunities.
As previously announced, the Company has identified several other critical cancers where it can leverage its diagnostic technology platform and has commenced biomarker identification and feasibility programs for each. in July 2022, Rhythm announced bioanalytical partner Agilex Biolabs and in December 2022 the Baker Institute who are engaged to support the development of the first two cancer programs.
Partnership with Nexomics
Rhythm has further progressed its feasibility programs, now confirming a third bioanalytical partner, Nexomics, at Peter MacCallum Cancer Center (PMCC), who have been engaged to advance proof of concept R&D for a third cancer program, gastric cancer.
Nexomics provides technical expertise for assessment of new diagnostic biomarkers against a “gold standard”. They offer a broad range of clinical tests for inclusion, safety monitoring, efficiency and exploratory biomarkers analysis using unparalleled access to clinical pathology samples.
PMCC is a world leading cancer treatment and research center, who values align with Rhythm’s goal of reducing worldwide cancer burden through early detection. PMCC will focus on feasibility and testing of preferred biomarker combinations with the greatest potential for early detection of gastric cancer.
Dr. Trevor Lockett, Technical Director & Board Member of Rhythm, commented:
“We are truly excited to work with an internationally recognised company such as Neomics & Peter MacCallum Cancer Center, that both understands the technology, shares the visions, and sees the significant opportunity to positively impact lives globally. This partnership strengthens our ability to leverage strong bioanalytical expertise to assess options for advancing our technology platform, while in parallel, the Company focuses its internal resources on accelerating our initial entry for ColoSTAT into international markets. We are looking forward to working with Nexomics to potentially identify an early screening test for gastric cancer in the future.”
